Gene
AKT3
AKT3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (5), Actionable biomarkers (2), Trial mentions (7), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention AKT3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
AKT3 has 7 trial mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 7 of 11,460 | 0.06% |
| 2022 | 0 of 8,285 | 0.00% | 7 of 13,598 | 0.05% |
| 2021 | 0 of 8,692 | 0.00% | 8 of 15,045 | 0.05% |
| 2020 | 0 of 7,640 | 0.00% | 10 of 14,459 | 0.07% |
| 2019 | 2 of 7,300 | 0.03% | 14 of 12,159 | 0.12% |
| 2018 | 1 of 6,927 | 0.01% | 7 of 11,854 | 0.06% |
| 2017 | 1 of 6,558 | 0.02% | 7 of 11,595 | 0.06% |
Showing 10 of 37 years.
Assay-provider ledger (5)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| NanoString Technologies | Unclassified | Clinical validationAnalytical validation | 1 | December 10, 2021 |
| AB Applied Biosystems | Reagent supplier | Clinical validation | 1 | Date unknown |
| Invitrogen | Reagent supplier | Clinical validation | 1 | Date unknown |
| LC Bio | Reagent supplier | Clinical validation | 1 | Date unknown |
| QIAGEN | Reagent supplier | Clinical validation | 1 | Date unknown |
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| AKT3 fusion | Gsk2141795 | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| AKT3 fusion | Azd5363 | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (7)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03310541 | Trial eligibility (AACT) |
| NCT05554380 | Trial eligibility (AACT) |
| NCT03834740 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT06425926 | Trial eligibility (AACT) |
Showing 5 of 7 trial mentions.
Target-disease associations (457)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Aganglionic megacolon | phenotype | Variant curation (ClinVar / EVA) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anxiety | phenotype | Literature (Europe PMC) |
| Bardet-Biedl syndrome | genetic, familial or congenital disease | Variant curation (ClinVar / EVA) |
Showing 5 of 457 associations.
Vendor sourcing (33)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The missense variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reporte... | View ClinVar record SCV002011935.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.431C>A (p.T144K) alteration is located in exon 5 (coding exon 5) of the AKT3 gene. This alteration results from a C to A substitution at nucleotide pos... | View ClinVar record SCV003586037.2 |
| Barrow Neurological Institute | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Prior resection of histologically-diagnosed WHO Grade III or IV glioma. A. Glioma patients who have progressed on or following standard (Stupp regimen)... | View trial NCT03834740 |
| Barrow Neurological Institute | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically diagnosed high-grade glioma (Grade 3 or 4 per 2021 WHO criteria) in the frontal lobe. * Tissue must demonstrate mTOR+: PTEN loss OR PIK3C... | View trial NCT05773326 |
| Barrow Neurological Institute | Trial collaborator | Mentioned in trial textTrial free-text mention | AKT3 | View trial NCT03834740 |
Showing 5 of 33 sourcing records.
Trial-cited literature (118)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Clinical application and detection techniques of liquid biopsy in gastric cancer. | Molecular cancer | 2023 | 160 |
| Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. | Cancers | 2023 | 89 |
| Hot Spots for the Use of Intranasal Insulin: Cerebral Ischemia, Brain Injury, Diabetes Mellitus, Endocrine Disorders and Postoperative Delirium. | International journal of molecular sciences | 2023 | 31 |
| Detection of brain somatic mutations in focal cortical dysplasia during epilepsy presurgical workup. | Brain communications | 2023 | 27 |
| Lipid metabolic vulnerabilities of multiple myeloma. | Clinical and experimental medicine | 2023 | 19 |
Showing 5 of 118 papers.
Protein variant mentions (4)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.E17K | 2 | 2019 to 2023 | PMID 37324239, PMID 31444548 |
| p.R465W | 2 | 2015 to 2018 | PMID 29758562, PMID 25741868 |
| p.V268A | 1 | 2015 | PMID 25741868 |
| p.Y414C | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (8)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Cryptorchidism | Disease | associate |
AKT3 and related molecules as potential biomarkers responsible for cryptorchidism and cryptorchidism-induced azoospermia. | 2021 |
| Hemimegalencephaly | Disease | associate |
Dissecting the genetic basis of focal cortical dysplasia: a large cohort study. | 2019 |
| Hypoglycemia | Disease | associate |
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. | 2012 |
| GATA2 Deficiency | Disease | associate |
Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. | 2010 |
| Agenesis of Corpus Callosum | Disease | associate |
Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. | 2007 |
Showing 5 of 8 relation assertions.
Organizations publishing (174)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 7 | 2012 to 2021 |
| The University of Texas System | Academic | 6 | 2009 to 2021 |
| Dana-Farber Cancer Institute | Other | 5 | 2009 to 2020 |
| Memorial Sloan Kettering Cancer Center | Hospital | 5 | 2011 to 2022 |
| Harris Health System | Hospital | 4 | 2010 to 2018 |
Showing 5 of 174 organizations.
Where AKT3 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
405 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.